Cost-Effective & Scalable Process Analytical Technologies in Biotech & Pharma
Demonstrating the Value of Efficient PAT, AI & Machine Learning in Drug & Biologics Development & Manufacturing to Ensure Product Consistency
As demand surged for GLP-1s, small molecules, and complex biologics, the industry faced increasing pressure to innovate and optimize manufacturing processes to meet the needs of Pharma 4.0. The 4th PAT & Real Time Quality Summit offered a unique opportunity to explore how Process Analytical Technology is transforming drug development and manufacturing, ensuring product consistency and reducing waste.Â
Across three days, 18+ industry leaders shared case studies, discussed the latest analytical tools, and demonstrated how digital technologies can be applied throughout the biologics and drug product lifecycle to save time and money. Attendees dived into key topics, including regulatory updates, real-time release testing, and tech transfer challenges, while exploring the application of PAT for various drug modalities, including CGT, vaccines, peptides, and small molecules.Â
With experts from top pharma companies such as AstraZeneca, GlaxoSmithKline, and Pfizer, this summit provided an unmatched platform to discuss strategies for improving processes and accelerating the adoption of scalable, cost-effective PAT solutions.
This wad your chance to connect with other PAT practitioners and gain the insights needed to navigate the future of pharma manufacturing.
2025 Event Guide
What Was New in 2025?
Interactive Regulatory Compliance Workshop
➜ You kickstarted your summit experience with the pre-conference workshop led by Farshid Mohammadparast of the US Pharmacopeia to discuss key recent regulations and guidelines that govern the use of PAT in
manufacturing of drugs and biological products
➜ You gained exclusive insights into understanding model validation workflows and addressing challenges for validating models for real time release testing (RTRT)
Putting PAT in Practice
➜ The 2025 summit shifted from exploring what’s possible in PAT to implementing what works. The focus was on real-world PAT execution, validation, and the organizational roadblocks that often stand in the way of adoption.
➜ You learned about strategies for validation, scale-up, and cross-functional buy-in from leading teams at Lonza, GSK, Johnson & Johnson and many more.
New Companies on the Agenda
Refreshed Speaker Faculty Including:
What Made Us Different?
"Was great to have the chance to be with leading PAT practitioners and exchange and discuss about the current trends, opportunities and challenges in the pharma business. I enjoyed many high-quality talks."
Head of Advanced Analytical Technologies, Roche
"The great opportunity to meet with PAT experts and share the advances and usage of PAT and chemometrics models within my company. Delighted to have learned more on other platforms such as Biotech and Cell and Gene Therapies."
Global Statistical & PAT Lead, Novartis
Previously Attending Companies Include:
World-Class Speaker Faculty in 2025 Included:
Shashi Prajapati
Director, Analytical Development, Head of Analytical Testing, Operations, Automation & Technologies
Vertex Pharmaceuticals
Darren Whitaker
Associate Director, Automation & Control in Process Chemistry Development
Takeda Pharmaceutical
Our 2025 Partners:
